Announcing a new publication for Acta Materia Medica journal. Endocrine therapy that blocks estrogen receptor signaling has been effective for decades as a primary treatment choice for breast cancer ...

The gonadotropin hormone receptors, including the follicle-stimulating hormone receptor (FSHR) and the luteinizing hormone/choriogonadotropin receptor (LH/CGR), serve as integral mediators of ...

A study led by researchers at the Hospital del Mar Research Institute advances one of the most significant milestones in breast cancer treatment, making immunotherapy effective against the most common ...

Chronic kidney disease (CKD) affects more than 10% of the global population and is expected to become the fifth leading cause of death worldwide within the next two decades. Perhaps surprisingly, ...

Estrogens are known to drive tumor growth in breast cancer cells that carry its receptors, but a new study by Duke Cancer Institute researchers unexpectedly finds that estrogens play a role in fueling ...

In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen receptor antagonist and degrader (SERD), when given as an adjuvant therapy ...

A mouse study suggests estrogen may increase gut pain by activating specific cells, offering hints to why IBS is more common ...

CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...